

03-03-06

1644

Express Mail Label No.: EV 695510665 US  
Date of Deposit: March 1, 2006

Attorney Docket No.: 25619-501

JFW



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Schoenfeld *et al.*  
SERIAL NUMBER: 09/806,400 EXAMINER: R. Schwadron  
FILING DATE: March 30, 2001 ART UNIT: 1644  
FOR: COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF  
ATHEROSCLEROSIS

**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of Cited References: A3-5; B4-5; C34-40; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 25619-501 RCE. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

for: Chal E. Bell Reg. No. 48,128  
for R. Elrifi, Reg. No. 39,529  
Matthew Pavao, Reg. No. 50,572  
Attorney/Agent for Applicants  
c/o MINTZ LEVIN  
Tel.: (617) 542-6000  
Fax: (617) 542-2241  
Customer No.; 30623

Dated: March 1, 2006



**THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Schoenfeld *et al.*  
SERIAL NUMBER: 09/806,400 EXAMINER: R. Schwadron  
FILING DATE: March 30, 2001 ART UNIT: 1644  
FOR: COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF  
ATHEROSCLEROSIS

**Mail Stop Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed due.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Shoenfeld et al.  
U.S.S.N.: 09/806,400

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 25619-501 RCE.

Respectfully submitted,

for:  Reg. No. 48,128  
Ivor R. Elrifi, Reg. No. 39,529  
Matthew Pavao, Reg. No. 50,572

Attorney/Agent for Applicants  
c/o MINTZ LEVIN


Tel.: (617) 542-6000

Fax: (617) 542-2241

**Customer No.; 30623**

Dated: March 1, 2006

TRA 2127032v.1



Express Mail: EV 6955 0965 US  
Date of Deposit: March 1, 2006

Page 1 of 1  
Attorney Docket No.: 25619-501 RCE

Please type a plus sign (+) in this box ☐

PTO/SB (12-97)  
Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Modified Form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>		09/806,400	
				<b>Filing Date</b>		March 30, 2001	
				<b>First Named Inventor</b>		Shoenfeld	
				<b>Group Art Unit</b>		1644	
				<b>Examiner Name</b>		R. Schwadron	
				<b>Attorney Docket Number</b>		25619-501	
<b>U.S. PATENT DOCUMENTS</b>							
<b>Exam Initials</b>	<b>Cite No.</b>	<b>U.S. Patent Document No.</b>	<b>Issue Date</b>	<b>Name of Patentee(s) or Applicant(s)</b>	<b>Class</b>	<b>Sub Class</b>	<b>Filing Date If Appropriate</b>
<b>U.S. PUBLISHED APPLICATION DOCUMENTS</b>							
<b>Exam Initials</b>	<b>Cite No.</b>	<b>U.S. Published Application No.</b>	<b>Published Date</b>	<b>Name of Patentee(s) or Applicant(s)</b>	<b>Class</b>	<b>Sub Class</b>	<b>Filing Date If Appropriate</b>
	A3	2004/0047870 A1	03/11/04	Harats et al.	424	184.1	
	A4	2005/0148499 A1	07/07/05	Harats et al.	514	8	
	A5	2005/0197283 A1	09/08/05	Harats et al.	514	8	
<b>FOREIGN PATENT DOCUMENTS</b>							
<b>Exam Initials</b>	<b>Cite No.</b>	<b>Foreign Patent Document Office Number</b>		<b>Name of Patentee(s) or Applicant(s)</b>	<b>Date of Publication</b>	<b>Translation Yes No</b>	
	B4	WO	01/68119 A1	KAROLINSKA INNOVATIONS AB	09/20/01		
	B5	WO	01/68124 a2	THE BRIGHAM AND WOMEN'S HOSPITAL, INC.	09/20/01		
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>							
<b>Exam Initials</b>	<b>Cite No.</b>	<b>Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.</b>					
	C34	Ameli et al. <i>Arterioscler. Thromb. Vasc. Biol.</i> , 16(8):1074-1079 (1996)					
	C35	Kobayashi et al. <i>J. Lipid Res.</i> , 42:697-709 (2001)					
	C36	Lindquist, S. <i>Ann. Rev. Biochem.</i> , 55:1151-1191 (1986)					
	C37	Maron et al. <i>Immunol. Lett.</i> , <b>Abstract 581</b> , 73(2-3):217 (2000)					
	C38	Schlesinger, M. <i>J. Cell Biol.</i> , 103:321-325 (1986)					
	C39	Xiao et al. <i>Clin. Immunol. Immunopathol.</i> , 85(2):119-128 (1997)					
	C40	Xu et al. <i>Arterioscler. Thromb.</i> , 12:789-799 (1992)					
<p>* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).</p>							
<b>Examiner Signature</b>				<b>Date Considered</b>			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.